Resistance to chemoimmunotherapy in non-small-cell lung cancer

Abstract

Recent clinical trials evaluating the combination of chemotherapy with immune checkpoint inhibition for the primary treatment of lung cancer showed increased progression-free and overall survival compared with chemotherapy alone. However, the combination of these two modalities is less than additive and the mechanisms of resistance to this therapeutic intervention are discussed here. So far, the conventional biomarkers for immunotherapy, namely programmed death-ligand 1 expression or tumor mutational burden are poor predictors of the efficacy of immunochemotherapy, and the optimal sequence of chemotherapy and immunotherapy has yet to be defined.

Keywords

Lung cancer / chemotherapy / immunotherapy combination / pembrolizumab / resistance

References

[1] Torre LA,Ward EM.Global cancer incidence and mortality rates and trends--an update..Cancer Epidemiol Biomarkers Prev2016;25:16-27

[2] Yoon SM,Hallman M.Therapeutic management options for stage III non-small cell lung cancer..World J Clin Oncol2017;8:1-20 PMCID:PMC5309711

[3] Peters S,Smit EF,Hellmann MD.How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer..Ann Oncol2019;30:884-96

[4] Baxevanos P.Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?.Ann Transl Med2018;6:139 PMCID:PMC5952027

[5] Olaussen KA.Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape..Ann Oncol2016;27:2004-16

[6] Wang C,Salgia R.Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer..Mol Ther Oncolytics2019;13:1-6 PMCID:PMC6444295

[7] McLaughlin J,Schalper KA,Pelekanou V.Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer..JAMA Oncol2016;2:46-54 PMCID:PMC4941982

[8] Garon EB,Hui R,Balmanoukian AS.Pembrolizumab for the treatment of non-small-cell lung cancer..N Engl J Med2015;372:2018-28

[9] Leighl NB,Hui R,Felip E.KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab..J Clin Oncol2017;35:9011

[10] Herbst RS,Kim D,Pérez-Gracia JL.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial..Lancet2016;387:1540-50

[11] Jean F,Barlesi F.Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy..Ther Adv Med Oncol2017;9:769-79 PMCID:PMC5808842

[12] Wang L,Qin K,Zhang X.Effect and biomarker of Nivolumab for non-small-cell lung cancer..Biomed Pharmacother2019;117:109199

[13] Maleki Vareki S,Duran I.Biomarkers of response to PD-1/PD-L1 inhibition..Crit Rev Oncol Hematol2017;116:116-24

[14] Schadendorf D,Robert C,Margolin K.Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma..J Clin Oncol2015;33:1889-94 PMCID:PMC5089162

[15] Fehrenbacher L,Ballinger M,Vansteenkiste J.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial..Lancet2016;387:1837-46

[16] Abdel-Rahman O.Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update..Immunotherapy2019;11:149-53

[17] Gandhi L,Gadgeel S,Felip E.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer..N Engl J Med2018;378:2078-92

[18] Langer CJ,Borghaei H,Patnaik A.Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study..Lancet Oncol2016;17:1497-508 PMCID:PMC6886237

[19] Socinski MA,Cappuzzo F,Stroyakovskiy D.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC..N Engl J Med2018;378:2288-301

[20] Cappuzzo F,Hussein M,Rittmeyer A.IMpower130: progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC..Ann Oncol2018;29:viii742-3

[21] Barlesi F,Cobo M,Paramonov V.IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)..Ann Oncol2018;29:viii743-4

[22] Lopes G,Kudaba I,Cho BC.Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study..J Clin Oncol2018;36:LBA4

[23] Paz-ares LG,Tafreshi A,Mazieres J.Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)..JCO2018;36:105-105

[24] Wan N,Hua SH,Ji B.Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC..Cancer Med2020;9:1683-93 PMCID:PMC7050096

[25] Galluzzi L,Kepp O,Kroemer G.Immunological effects of conventional chemotherapy and targeted anticancer agents..Cancer Cell2015;28:690-714

[26] Zitvogel L,Smyth MJ.Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance..Immunity2013;39:74-88

[27] Kepp O,Martins I,Adjemian S.Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy..Cancer Metastasis Rev2011;30:61-9

[28] Wang Z,Gao Q.Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells..Oncoimmunology2017;6:e1331807 PMCID:PMC5543863

[29] Rizvi NA,Brahmer JR,Borghaei H.Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer..J Clin Oncol2016;34:2969-79 PMCID:PMC5569693

[30] Gadgeel SM,Langer CJ,Borghaei H.Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C..JCO2016;34:9016-9016

[31] Liu SV,Gettinger SN,Heist RS.Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer..Eur J Cancer2018;101:114-22

[32] Liu SV,Gettinger SN,Heist RS.Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study..J Clin Oncol2017;35:9092-9092

[33] Li JX,Jiang ZB,Sun A.Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer..Integr Cancer Ther2019;18:1534735419890020 PMCID:PMC7242804

[34] Apetoh L,Coukos G.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?.Ann Oncol2015;26:1813-23

[35] Qiao M,Ren S.Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer: where do we stand?.Clin Lung Cancer2018;19:1-11

[36] Liu WM,Smith P.Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses..Br J Cancer2010;102:115-23 PMCID:PMC2813751

[37] Suzuki E,Jassar AS,Albelda SM.Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity..Clin Cancer Res2005;11:6713-21

[38] Larsson AM,Leandersson K.Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer..Sci Rep2019;9:13451 PMCID:PMC6748932

[39] Lesterhuis WJ,Hato SV,Jansen BJ.Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice..J Clin Invest2011;121:3100-8 PMCID:PMC3148725

[40] Lesterhuis WJ,Nowak AK,Khong A.Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity..PLoS One2013;8:e61895 PMCID:PMC3633941

[41] Ghiringhelli F,Puig PE,Roux S.Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients..Cancer Immunol Immunother2007;56:641-8

[42] Leonetti A,Mazzaschi G,Rolfo C.Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer..Drug Resist Updat2019;46:100644

[43] Serrano A,Lionello I,Traversari C.Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2’-deoxycytidine treatment..Int J Cancer2001;94:243-51

[44] Pfirschke C,Rickelt S,Garris C.Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy..Immunity2016;44:343-54 PMCID:PMC4758865

[45] Ganss R,Klar E,Hämmerling GJ.Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication..Cancer Res2002;62:1462-1470

[46] Rettig L,Parvanova I,Curioni A.Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells..Int J Cancer2011;129:832-8

[47] Sharma P,Wargo JA.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy..Cell2017;168:707-23 PMCID:PMC5391692

[48] Gubin MM,Schuster H,Ward JP.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens..Nature2014;515:577-81 PMCID:PMC4279952

[49] Sucker A,Real B,Bielefeld N.Genetic evolution of T-cell resistance in the course of melanoma progression..Clin Cancer Res2014;20:6593-604

[50] Chen PL,Reuben A,Spencer CN.Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade..Cancer Discov2016;6:827-37 PMCID:PMC5082984

[51] Tun AM,Thein WL.Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials..Future Sci OA2019;5:FSO421 PMCID:PMC6787520

[52] Dafni U,Vervita K.Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis..Lung Cancer2019;134:127-40

[53] Addeo A,Metro G.Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis..Front Oncol2019;9:264 PMCID:PMC6478036

[54] Wu J.Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy..Cancer Lett2018;419:210-21 PMCID:PMC5818299

[55] Melosky B,Hirsh V,Leighl N.Amplifying outcomes: checkpoint inhibitor combinations in first-line non-small cell lung cancer..Oncologist2020;25:64-77 PMCID:PMC6964132

[56] Yan Y,Finnes H,Park S.Combining immune checkpoint inhibitors with conventional cancer therapy..Front Immunol2018;9:1739 PMCID:PMC6072836

[57] Rassy E,Assi T,Pavlidis N.The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?.Immunotherapy2019;11:913-20

[58] Coffelt SB.Immune-mediated mechanisms influencing the efficacy of anticancer therapies..Trends Immunol2015;36:198-216

[59] Reck M,Luft A,Barlesi F.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial..Ann Oncol2013;24:75-83

[60] Reck M,Lee A,McCleland M.Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations..Expert Rev Respir Med2020;14:125-36

[61] Ogawara D,Iwasaki K,Taniguchi H.Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy..Thorac Cancer2018;9:175-80 PMCID:PMC5754301

[62] Park SE,Ahn JS,Park K.Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer..J Thorac Oncol2018;13:106-11

[63] Saleh R.Treg-mediated acquired resistance to immune checkpoint inhibitors..Cancer Lett2019;457:168-79

[64] Vera Aguilera J,McWilliams RR,Li Y.Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients..Melanoma Res2020; PMCID:PMC7331824

[65] Yan Y,Liu X,Bindeman WE.CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy..JCI Insight2018;3:97828 PMCID:PMC5931117

[66] Leontovich AA,Suman VJ,Nevala WK.Fluctuation of systemic immunity in melanoma and implications for timing of therapy..Front Biosci (Elite Ed)2012;4:958-75

[67] Chang CL,Wu CC,Wang C.Dose-dense chemotherapy improves mechanisms of antitumor immune response..Cancer Res2013;73:119-27 PMCID:PMC3537885

[68] Chatwal MS.Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?.Transl Lung Cancer Res2018;7:S208-10 PMCID:PMC6193911